VT Ablation in Cardiolaminopathies
a clinical phenotype suggestive of or a confirmed family history of a LMNA mutation. The 122 patients who had a confirmed pathogenic LMNA mutation were included for further review (S. Kumar et al, unpublished data, 2016). Of these 122 patients, 45 patients developed sustained ventricular tachycardia requiring external shock, antiarrhythmic drugs (AADs), and therapies by the implanted cardioverter-defibrillator for termination. Of these 45 patients, 25 patients underwent electrophysiological study with catheter mapping and ablation between 2008 and 2015 at 4 of the 5 included centers and are the subject of the current report. All patients gave written informed consent for the procedure; procedures were performed according to protocols approved by each of the institutions' Subject Protection Committee.
Mapping and Radiofrequency Ablation
Procedures were performed under conscious sedation or general anesthesia as described previously. [10] [11] [12] [13] Mapping and ablation were performed using a 3.5-mm tip irrigated catheter (NaviStar ThermoCool, ThermoCool SF or Thermocool SMART-TOUCH; Biosense Webster, Diamond Bar, CA and Safir BLU or Therapy CoolPath, St. Jude Medical, St. Paul, MN). Endocardial/epicardial voltage maps were created using a three-dimensional (3D) electroanatomic mapping system (CARTO, Biosense Webster or Ensite NavX, St. Jude Medical).
14 Bipolar electrogram amplitude of <1.5 mV was defined as lowvoltage zone consistent with scar. Dense scar was defined as voltage ≤0.5 mV. 15 Electrically unexcitable scar was defined as sites where the unipolar pacing threshold exceeded 10 mA with 2-ms pulse width. 14 Image integration with preprocedural contrast-enhanced magnetic resonance imaging or computer tomography scans were used, when available, to identify and reconstruct scar anatomy and were imported into the 3D mapping system. 16 Epicardial mapping was performed using the percutaneous approach if VT was suspected to be of epicardial origin. 17 Coronary angiography was performed before epicardial ablation to avoid coronary injury. The chamber (left ventricle [LV] or right ventricle [RV] and space [endo/epicardial]) mapped was based on the characteristics of the induced or spontaneous VA. 17 For the purpose of scar characterization, the ventricles were divided into basal, mid, and apical one third regions of each chamber.
Programmed ventricular stimulation was performed with at least 3 extrastimuli at least 2 drive trains (typically 600 and 400 ms) from at least 2 RV sites. LV stimulation and isoprenaline were used if VA was noninducible after right ventricular stimulation. The same induction protocol was repeated post ablation if the patient's hemodynamic status permitted.
Spontaneous VT was defined as any inducible VT that had a 12-lead electrocardiograph morphology and rate (within 20 ms) matching a VT that had documented to have occurred spontaneously before ablation; only the rate cutoff and intracardiac electrogram data from the implanted cardioverter-defibrillator were used when the 12-lead VT morphology was not available before ablation. Nonspontaneous VTs were inducible VTs that did not have an identical rate (>20 ms difference) or 12-lead EKG morphology to the spontaneously documented VT before ablation. 10 The mechanism of VT was defined as scar-related reentry when more than one of the following was present: induction and termination was demonstrable with programmed ventricular stimulation, fulfilled criteria for transient entrainment, had an exit site at a lowvoltage area consistent with scar, had evidence of slowed conduction with pace maps in this region yielding a stimulus-to-QRS delay of >40 ms, and when ablation in the putative isthmus region abolished, >1 morphology of VT. Reentry circuit sites were defined by entrainment and pace mapping as reported previously. 18 The site of successful ablation of VTs was defined on the basis of a combination of more than one of suggestive surface EKG morphology, site of 12/12 pace maps, activation and entrainment mapping identifying the VT isthmus and exit, and site of successful termination with ablation without reinduction of the same VT. EKG features suggestive of a basal exit were left bundle (LB) morphology in V 1 with early precordial transition ≤V 3 or right bundle (RB) morphology in V 1 with positive concordance. 16 EKG features suggestive of an apical exit were those with LB morphology in V 1 and precordial transition ≥V 5 or RB morphology in V 1 with precordial transition ≤V 3 , as described previously. 19 Ablation was based on activation and substrate mapping depending on the inducibility and hemodynamic tolerance of induced VT. Ablation targeted presumptive isthmii and exits, based on activation and entrainment mapping, if VT was hemodynamically tolerated. 18 If VT was not hemodynamically tolerated or was not inducible, substrate-based ablation was performed. The approach varied according to the procedural center but typically involved targeting presumptive channels and exits as identified from a paced QRS morphology being similar to the VT QRS morphology with stimulus-QRS interval >40 ms, abnormal fractionated potentials, double potentials, late potentials during sinus or paced rhythm at sites where pacing captured, and late abnormal ventricular activities. 10, 11 Irrigated radiofrequency ablation was delivered at a power of 25 to 50 W targeting an impedance drop of 10 to 20 ohms. Applications were repeated at target areas until one or more of the following occurred: (1) the site was rendered electrically unexcitable with unipolar pacing at 10 mA at 2-ms pulse width and (2) complete late abnormal ventricular activity elimination occurred. Additional substrate ablation was performed if the targeted VA remained inducible and residual late abnormal ventricular activities were present during repeat mapping. 10, 11 Adjunctive nonradiofrequency ablative modalities such as transcoronary ethanol ablation or surgical cryoablation were performed if AADs and attempts at endo-and epicardial mapping (where relevant) failed to control VA. Transcoronary ethanol ablation and surgical cryoablation were performed using techniques reported previously. 20 Existence of an intramural VT circuit was inferred when earliest activation or the closest sites to the reentry circuit were on either side of the septum (if the QRS morphology was consistent with a septal origin 21 ) or on either side of the endo-or epicardial space mapped (if nonseptal origin) and ablation failed to terminate VT, and there was evidence of intramural scar from bipolar or unipolar voltage abnormality with electrogram amplitude <5.5 mV for the RV 22 and <8.3 mV in the LV or the interventricular septum 23 or cardiac magnetic resonance imaging. 16 
Outcomes
Outcomes were reported as complete success (noninducibility of any VT, spontaneous and nonspontaneous), partial success (abolishment of at least 1 spontaneous VT), and failure (residual inducibility of spontaneous VT). 10, 20 Long-term outcomes reported included (1)
WHAT IS KNOWN
• LMNA cardiomyopathy is an inherited, genetic disorder characterized by progressive conduction abnormalities, atrial arrhythmias, dilated cardiomyopathy and ventricular arrhythmias.
• Up to 52% of LMNA cardiomyopathy patients may experience appropriate defibrillator therapies for ventricular arrhythmias.
WHAT THE STUDY ADDS
• In patients with LMNA cardiomyopathy and drug refractory VT who underwent catheter ablation, VT was consistent with origin from scar in the basal left ventricle, particularly the septum, but also basal inferior wall and subaortic mitral continuity.
• Catheter ablation was associated with poor outcomes including high rate of arrhythmia recurrence, progression to end stage heart failure and high mortality. VT Ablation in Cardiolaminopathies survival free of any VA after a single and after multiple procedures; (2) arrhythmia control defined as any reduction in the number of VA episodes or number of AADs required for arrhythmia control during follow-up; (3) overall survival; and (4) survival free of death or cardiac transplantation.
Follow-Up
Follow-up included review of records of all hospital and outpatient clinic visits and discussion with referring cardiologists and primary care physicians. AADs prescribed long term were either continued at the same or reduced dose or, discontinued, as per the treating physician. AADs initiated recently to control multiple/incessant VT were discontinued. Programming of the implanted cardioverter-defibrillator or cardiac resynchronization therapy defibrillator was left to the treating physician; however, in general, a minimum of 2 zones were programmed. The first zone was set at a rate least 20 ms below the rate of the slowest spontaneous or inducible VT with or without therapy with antitachycardia pacing, and a second zone had a minimum rate cutoff of >188 beats per minute programmed to deliver shock with or without antitachycardia pacing. Where possible, programming was kept consistent before and after an ablation procedure.
Statistical Analysis
The Statistical Package for the Social Sciences for Windows (IBM SPSS, release 23, Armonk, NY) was used for analysis. Continuous variables were expressed as mean±SD if normally distributed; median and interquartile range 25% to 75% (Q25-Q75) or full ranges were used if the data were clearly skewed. Where normal distribution was not present, log transformation of the raw values was performed to meet the assumption of homogeneity of variance. Where applicable, paired sample t test was performed using the raw values (if normally distributed) or log-transformed values (if not normally distributed). Procedural success, overall survival, and survival free of death or cardiac transplant were estimated using the Kaplan-Meier procedure. A 2-tailed P value <0.05 was considered statistically significant.
Results

Patient Demographics
Of the 25 patients who had electrophysiology study, the mean age was 55±9 years (23 men, mean LV ejection fraction 34±12%; Table 1 ). Patients presented for electrophysiology study with drug-refractory sustained monomorphic VT after a median of 6 years from first clinical contact. At this point, they had failed a median of 2 AADs, including amiodarone in 72% of patients. Some form of atrioventricular block was present in 88% of patients, including complete atrioventricular block in 48%; and 60% of patients were receiving heart failure therapies at the time of first ablation including mechanical circulatory support in the form of a ventricular assist devices in 12% of patients.
Procedural Data
A total of 47 ablation procedures were performed during a median of 7 months (Q25-Q75, 2-15 months; Table 2 and Figure 1 ). Procedural indication was sustained monomorphic VT for all procedures. A single procedure was performed in 11 patients; multiple procedures were performed in 14 patients (2, 3, or 4 procedures in 8, 4, and 2 patients, respectively) because of drug-refractory VT not controlled after ≥1 procedures. VT storm prompted 36% of procedures. In 1 patient, ablation was not performed because of absence of inducible VT (excluded from analysis of acute procedural outcomes and follow-up). In another patient, surgical cryoablation was performed as part of left ventricular assist device insertion in whom VT had recurred after 3 percutaneous catheter ablation procedures. Eight patients received adjunctive nonradiofrequency ablation techniques including transcoronary ethanol ablation (6 patients) or surgical cryoablation (2 patients).
Electroanatomic Mapping Features
An electroanatomic voltage map during sinus rhythm was performed in 22 patients (the remaining 3 patients had VT ablation guided by activation/entrainment mapping; Figure  I in the Data Supplement). Endocardial mapping data were available in 19 out of 25 patients for the LV and in 13 out of 25 patients for the RV; epicardial mapping data were available in 7 patients. Low-voltage endocardial LV scar was present in all 18 out of 19 patients (95%) mapped (1 patient had epicardial scar alone; and in 1 patient the septum and the basal inferior wall were not mapped). Endocardial RV scar was present in 8 out of 13 patients (72%) mapped. Epicardial scar was present in 6 out of 7 patients (75%). Figure 2 summarizes the location of scar according to chamber mapped. In the LV, scar was most commonly found in the basal antero-or inferoseptum (78% of patients), subaortic mitral continuity (53%), mid antero-or inferoseptum (50%), basal inferior wall (39%), or mid inferior wall (28%; Figure 2A ). In the RV, scar was most commonly found in the basal antero-or inferoseptum (46%; Figure 2B ). In the 7 patients with epicardial mapping, epicardial scar was commonly found overlying the basal inferior LV (71%), basal or mid lateral LV (29% each, respectively), LV summit or basal anterior LV (29%), or the apex (29%; Figure 2C ). When present, epicardial scar overlay the corresponding endocardial region in all but 1 patient; this patient had isolated basolateral epicardial scar with no endocardial scar.
Notably, endocardial septal scar was present in all but 1 patient (who had no other scar in the LV and had epicardial scar only). Basal perivalvular scar was present in all but 1 patient. Only 6 out of 17 patients had scar limited to the basal LV; 11 patients had scar extending from the basal to mid LV, of which 5 patients had contiguous scar extending from the base to the apex. Two patients had isolated scar with no other LV regional involvement (basal inferior LV alone and mid lateral LV alone). When scar was present, it involved the RV septum in 7 out of 8 patients. In all patients, endocardial unipolar low-voltage area was more extensive than the bipolar low-voltage area in all cases; this was particularly pronounced for the septum. Typical examples are shown in Figures 3 and 4 (also in Figures II and III in the Data Supplement).
Characteristics of Inducible VTs and Sites of Ablation
A total of 171 VTs were inducible or seen spontaneously during the procedure for 47 procedures (median of 3 VTs per procedure, Q25-Q75, 2-6). Mean cycle length of induced VT was 422±109 ms (median 407; Q25-Q75, 340-492 ms). Complete analysis of VT morphology was possible in 147 VAs after exclusion of 5 VTs with indeterminate morphology VT Ablation in Cardiolaminopathies due to ventricular-flutter like configuration at rapid rates (5 VTs), EKG artifacts or missing leads that precluded accurate classification (12 VTs). All but 2 VTs were attributed to reentry related to regions of scar; in the remaining 2 patients, one had right ventricular outflow tract VT and another patient had papillary muscle VT of focal origin in the absence of scar in those regions. VTs were inducible with programmed stimulation or conversion from another VT (72%), spontaneously present or incessant at the start of the procedure (20%), induced by catheter manipulation (7%), or inducible with atrial pacing (1%).
Observed VT morphologies were RB inferior axis (32%), RB superior axis (28%), LB inferior axis (22%), and LB superior axis (12%). Typical morphologies and site of successful ablation are shown in Table I and Figure IVA through IVC in the Data Supplement.
In 10% of VTs, atypical morphologies were seen, similar to those described elsewhere previously. 21 The first of these morphologies was one that exhibited inferior limblead disconcordance where LB morphology was seen in V 1 with a net positive vector in II, negative in III, and positive in aVL. This morphology was ablated at the endocardial basal septal RV (3 VTs). The second and third pattern were of either reversed disconcordance with a RB morphology in V 1 , negative vector in II, and positive in III (6 VTs) or a pattern break with RB morphology in V 1 and V 3 with reversal of this in V 2 , both of which were terminated with ablation in the endocardial basal septal LV (1 VT) and were no longer inducible.
In 7 VTs, a qR or rS pattern in lead V 1 with a rS or a Rs pattern throughout the precordial leads was seen. These VTs were always ablated in the LV or RV side of the basal inferoseptum ( Figure IVC in the Data Supplement). 
VT Ablation in Cardiolaminopathies Catheter Ablation and Acute Procedural Outcomes
Ablation was performed in all but 1 patient (described above) who had no inducible VT at the beginning of the procedure. This patient was excluded from analysis of outcomes. Procedural outcomes are summarized in Figure 1 and Table 3 . After multiple procedures, complete success was achieved in only 6 out of 24 patients (25%), partial success in 12 out of 24 patients (50%), and failure in 3 out of 24 patients (12.5%). Three out of 24 patients (12.5%) did not undergo repeat testing at the end of the procedure to avoid hemodynamic stress. In general, acute procedural success declined after each subsequent procedure (Table 3) .
Complete success could not be achieved in 18 out of 24 patients which was predominantly attributed to basal septal intramural substrate (13 patients; 72%), lateral intramural substrate (1 patient), VT origin from a site protected by epicardial coronary branches (1 patient; mid size circumflex and obtuse marginal), or the inaccessible region of the epicardial LV summit (1 patient), presumed origin in the aortic root close to left main (1 patient) or an acute procedural complication in a patient who experienced asystole and refractory cardiogenic shock necessitating procedure termination.
Acute procedural complications occurred in 5 out of 25 patients (25%). Complications included anticipated complete AVB in 2 patients (1 patient post RFA and 1 patient post transcoronary ethanol ablation), asystole and cardiogenic shock in 2 patients, and stroke in 2 patients (of which 1 patient had cardiogenic shock and stroke). One patient died within 30 days post procedure from cardiogenic shock refractory to mechanical circulatory support.
Outcomes in Follow-Up
The number of procedures and outcomes after every procedure is summarized in Figure 1 . In summary, at a median followup of 7 months (Q25-Q75, 1-27 months), cumulative event rate for VT recurrence after a single procedure was 91±6% and after multiple procedures was 83±9%. However, patients had a median of 1.5 shocks (Q25-Q75, 0-9 shocks) for VT in the month before ablation, and this fell to a median of 0 shocks (Q25-Q75, 0-1; P=0.1) in the 6 months after ablation. There was a statistical trend toward reduction in the number of AADs required for arrhythmia control after ablation (mean 2.6±1.2 before ablation to 1.5±0.9 after ablation; P=0.06).
By the end of follow-up, 11 out of 25 patients (44%) had received or were awaiting advanced heart failure therapies. Left ventricular assist devices had been placed in 6 patients (present before ablation in 3 patients), 3 patients had received cardiac transplantation, and 2 patients were awaiting At the end of follow-up, 11 patients had died (details in Table II in the Data Supplement). After median follow-up of 7 months, cumulative estimate for all-cause mortality was 26±11%. Cumulative estimate for death or transplantation was 31±11%. The causes of death were refractory heart failure (6 patients), or complications related to either ventricular assist devices (3 patients) or to cardiac transplantation (1 patient). One patient with a cardiac resynchronization therapy defibrillator died suddenly because of ventricular fibrillation refractory to multiple shocks.
The relationship between type of genetic mutation, scar distribution, and outcomes in follow-up is summarized in Table III in the Data Supplement. Notably, patients with nonmissense mutations compared with those with missense mutations had a significantly higher mortality (at median follow-up of 7 months 18% versus 0%, respectively; P=0.02) and a trend toward higher rate of death or transplant (27% versus 0%; P=0.2) but similar rate of VT recurrence (89% versus 82%; P=0.7) after the final procedure.
Discussion
This multicenter study describes the experience with catheter ablation of patients with LMNA cardiomyopathy who 1. VTs in this population predominantly seem to be related to reentry in and around regions of scar; 2. Based on 12-lead EKG, pace mapping, activation and entrainment mapping, and site of successful ablation without reinduction of the same VT, the majority of VTs seem to originate from scar in the basal septum exiting toward the LV. 3. Despite multiple procedures, including transcoronary ethanol ablation or surgical cryoablation, inducible VT was abolished in only 25% patients, which seemed to be largely because of intramural substrate. Furthermore, procedure complications were significant (25% of patients). 4. VT recurred in 83% of patients after multiple procedures, although a trend toward reduction in defibrillator shocks and AAD use achieved. 5. Perhaps most concerning was the fact that nearly half of the patients required subsequent advanced heart failure therapies and almost one third died of heart failurerelated complications or required cardiac transplantation within a short time period (7 months).
These findings suggest that patients with LMNA cardiomyopathy who develop drug-refractory VTs are a high-risk Numerator denotes number of patients with outcome divided by the number of patients included the analysis. Parentheses represent percentage. VT indicates ventricular tachycardia.
*One patient had no inducible VT at start of the procedure, no radiofrequency was delivered, and excluded from the outcome analysis. Forty-five-year-old man with LMNA cardiomyopathy (ejection fraction 40%) who developed recurrent VT and defibrillator shocks that failed to respond to amiodarone and β-blockers. Seven VTs were inducible mapped to the small region of bipolar low-voltage scar (but much larger unipolar scar) in the periaortic region, basal septal LV, and the aortic-mitral continuity. Despite multiple procedures, VTs remained inducible, and frequent recurrences occurred, necessitating listing for cardiac transplantation. The patient, however, died of refractory heart failure while awaiting transplant. VT Ablation in Cardiolaminopathies population in whom arrhythmia control with catheter ablation remains extremely challenging with a high failure and recurrence rates. Moreover, the onset of drug-refractory VT may be a harbinger of heart failure, need for transplant, or mortality, suggesting the need for escalated efforts toward supportive advanced heart failure therapies at the onset of drug-refractory VT.
Previous Studies
LMNA cardiomyopathy is an important cause of familial dilated cardiomyopathies, accounting for 5% to 8% of cases. 24 The cardiac phenotype is well characterized notably for atrial arrhythmias and progressive atrioventricular conduction disease that precedes the development of malignant VAs, ventricular dilatation, dysfunction, and heart failure by several years. 3, 4, 6, 7 Typically, the disease course is more aggressive than other forms of idiopathic dilated cardiomyopathies in terms of progression to end-stage heat failure or tendency for malignant VAs. 7 Distinct from other dilated cardiomyopathies, malignant VAs and sudden death may occur in the absence of significant ventricular dilatation or dysfunction. 2, 9 Pacemaker therapy to abrogate atrioventricular dysfunction does not reduce risk of 25, 26 Indeed, sudden death is thought to account of ≤46% of deaths in this population 25, 26 and therapies for VA are reported to occur in up to 52% of patients with defibrillators. 2, 9 In the presence of compelling data for VAs in this population, there is lack of published data on experience with catheter ablation in this population.
Previous imaging studies have implicated midmyocardial basal septal fibrosis, detected as late gadolinium enhancement and reduced septal strain as a common pathogenic mechanism linking progressive atrioventricular conduction disease and substrate for VAs in this population. [27] [28] [29] One important study of a Finnish family found isolated local hypokinesia and thinning of inferoposterior area LV on imaging with localized thinning and fibrosis in the inferoposterior area of the LV, with only minimal fibrosis in the right ventricle and no abnormalities in the interventricular septum on autopsy of a deceased proband. 30 Another study reported fibrosclerotic degeneration of the atrioventricular node with less severe lesions in the sinoatrial node, atrium, and ventricular walls in this population. 31 Our study is consistent with these observations in that the majority of our patients had some form of atrioventricular block at the time of their first ablation and that low-voltage scar in the basal septum/subaortic mitral continuity and basal inferior LV was evident serving as electrophysiological substrate for VT. The combination of intramural substrate and the basal perivalvular scar (where catheter stability may be difficult to maintain) may have contributed to poor ablation outcomes in this population. Uniquely, we described that VTs are invariably attributed to reentry in and around these regions of scar with limited success with contemporary ablation techniques attributed to the presence of intramural substrate. The substrate in this population is more consistent with the anteroseptal subtype as described previously among the nonischemic cardiomyopathy population. 12, 32 Although the inferolateral subtype was also seen, this accounted for <10% of all observed VAs. 16, 32 Also consistent with previous reports, ablation was frequently required in the septal left ventricular endocardium, procedural success was lower, repeat procedures were required in many patients, and arrhythmia recurrence was higher. 16, 32 Akin to the experience from a large multicenter study that found a high event rate (72%) for sudden cardiac death, VAs, or end-stage heart failure, we found that despite multiple catheter ablation attempts to achieve control of VA, there was inexorable progression to heart failure (44%) and need for transplantation or mortality (31%) in this ablated cohort. Although VA control was achievable with a numeric reduction in shock burden and AAD use, it was offset by a high procedural complication rate (25%). Our findings suggest that ablative therapy may be palliative to allow VA control but do little to alter the natural history of disease progression, which was typically rapid with most heart failure, transplant, and mortality events occurring within 7 months from the last ablative effort. Notably, the number of biventricular implants for escalated RV pacing and advanced AVB increased from 9 patients (36%) at presentation to 15 patients (60%) at the end of follow-up, which may have contributed to the increased burden of end-stage heart failure after ablation. These findings underscore the critical importance of supportive heart failure therapy in this population.
Limitations
The experience reported in this study is drawn from multiple tertiary referral centers accumulated over almost a decade; as such, these patients may represent those with the most severe disease. The small sample size and variability in ablation approaches limits the statistical interpretation of meaningful differences between outcomes and does not allow appropriate adjustment to be performed; hence, mainly descriptive statistics are used. It nevertheless is one of the largest series in this rare disorder and lends critical insights into the VT ablation in this population, not otherwise reported thus far. Although ablation was based on common principles of activation/ entrainment mapping when VT was hemodynamically tolerated in addition to substrate mapping or substrate mapping alone when VT was not hemodynamically tolerated, there were minor differences in substrate targets between centers, which may have introduced some variability in the outcomes. Because this was not a prospective study, complete biventricular endo and epicardial voltage mapping data were not obtained in all patients; rather, patients underwent clinically indicated ablation for arrhythmia control with voltage mapping limited to the putative origin of VT. Therefore, the frequency of electrophysiologically abnormal areas, particularly in the subepicardium, may be underestimated.
Only 7 out of 25 patients underwent epicardial mapping in this study. The majority of spontaneous or inducible VTs arose from the basal septum based on pace mapping, activation and entrainment mapping, and site of successful ablation without reinduction of the same VT in morphology. However, one of the striking findings in our study is that the basal septum is almost uniformly involved in causing VT in these patients. As recently recognized, basal septal substrate is a common source of VT in nonischemic cardiomyopathies and that VTs from this substrate are rarely ablated from the epicardium because of overlying RV outflow tract, fat, and the coronary arteries. 12, 32 It is possible that routine complete endo and epicardial mapping could have potentially identified more areas of electrically abnormal myocardium. In the absence of basal septal VT, complete endo and epicardial mapping could have potentially improved procedural success in this cohort.
Conclusions
Multicenter experience with percutaneous catheter ablation of drug-refractory VT in patients with LMNA cardiomyopathy suggests poor acute procedural success rates, a high rate of procedural complications, and near-universal arrhythmia recurrence. Patients seem to have predominantly basal septal or basal inferior left ventricular substrate capable of supporting multiple reentrant VTs related to regions of scar. Arrhythmias are frequently of intramural origin making VA control extremely challenging. Ablation seems to be of palliative benefit. There is a high rate of heart failure and need for mechanical circulatory support, transplantation, and mortality after catheter ablation. 
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